David C.W. Lau, MD, PhD
Julia McFarlane Diabetes Research Centre and Libin Cardiovascular Institute
Biography & Research Background
David C.W. Lau, MD, PhD is based at the Julia McFarlane Diabetes Research Centre and Libin Cardiovascular Institute of Alberta, University of Calgary Cumming School of Medicine. He led the Phase 2 dose-finding study and Phase 1b safety/tolerability trials that established the dose-dependent weight loss effects of cagriniltide monotherapy and its safety profile when co-administered with semaglutide. His key publications include "Once-weekly cagrilintide for weight management in people with overweight and obesity" (2021, The Lancet) and "Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of cagrilintide with semaglutide" (2021, The Lancet). David C.W. Lau is being referenced as one of the leading scientists involved in cagriniltide research. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between Pure US Peptide and this doctor.
External Profiles
Authored Research Profiles (1)
David C.W. Lau, MD, PhD is referenced as a leading researcher in the following peptide research profiles on Pure U.S. Peptides:
David C.W. Lau, MD, PhD is being referenced as one of the leading scientists involved in the research and development of the peptides listed above. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of any product for any reason. There is no affiliation or relationship, implied or otherwise, between Pure U.S. Peptides and this researcher. The purpose of citing the researcher is to acknowledge, recognize, and credit the exhaustive research and development efforts conducted by the scientists studying these peptides.